GOVX vs. SKYE, DTIL, IKNA, KPTI, RENB, ARTV, OTLK, VNRX, PEPG, and ATNM
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Skye Bioscience (SKYE), Precision BioSciences (DTIL), Ikena Oncology (IKNA), Karyopharm Therapeutics (KPTI), Renovaro (RENB), Artiva Biotherapeutics (ARTV), Outlook Therapeutics (OTLK), VolitionRx (VNRX), PepGen (PEPG), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "pharmaceutical products" industry.
GeoVax Labs vs.
Skye Bioscience (NASDAQ:SKYE) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 4.5% of Skye Bioscience shares are held by insiders. Comparatively, 1.2% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Skye Bioscience presently has a consensus price target of $16.60, indicating a potential upside of 656.26%. GeoVax Labs has a consensus price target of $11.10, indicating a potential upside of 1,032.77%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Skye Bioscience.
Skye Bioscience has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.47, meaning that its stock price is 247% more volatile than the S&P 500.
In the previous week, Skye Bioscience had 6 more articles in the media than GeoVax Labs. MarketBeat recorded 7 mentions for Skye Bioscience and 1 mentions for GeoVax Labs. Skye Bioscience's average media sentiment score of 0.51 beat GeoVax Labs' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.
GeoVax Labs received 30 more outperform votes than Skye Bioscience when rated by MarketBeat users.
GeoVax Labs has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Skye Bioscience's return on equity of -45.78% beat GeoVax Labs' return on equity.
Summary
Skye Bioscience and GeoVax Labs tied by winning 8 of the 16 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GeoVax Labs Competitors List
Related Companies and Tools
This page (NASDAQ:GOVX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy GOVX Stock Free GOVX Stock Alerts